Patent ID: 6908921

Claim:
A compound of formula I and pharmaceutically acceptable salts thereof, wherein X is selected from (1) —(CH 2 ) m C(O)NR b —, (2) —(CH 2 ) m NR b C(O)—, (3) —(CH 2 ) m C(O)O—, (4) —(CH 2 ) m S(O) m —, (5) —(CH 2 ) m O—, (6) —(CH 2 ) m NR b —, (7) —C(O)—, (8) HC═CH, and (9) —(CH 2 ) m —; Y is selected from (1) —C(O)—, (2) —C(O)O—, (3) —SO 2 — and, (4) —CH 2 —; R 1 is (CH 2 ) n -phenyl substituted with a group selected from 1-imidazolyl, 2-imidazolyl, 4,5-dihydro-2-imidazolyl, and 1,2,4-triazol-4-yl; wherein the imidazolyl, dihydroimidazolyl, and triazolyl rings are each optionally substituted with 1 or 2 C 1-4 alkyl groups; R 2 is selected from: (1) C 1-6 alkyl optionally substituted with 1 to 3 halogen atoms, (2) C 3-7 cycloalkyl, (3) aryl, (4) ara-C 1-4 alkyl, wherein aryl and aralkyl are optionally substituted with 1 to 4 groups independently selected from halogen, C 1-4 alkyl optionally substituted with 1 to 5 halogen atoms, hydroxy, C 1-4 alkoxy optionally substituted with 1 to 5 halogen atoms, nitro, cyano and NR b R c ; and wherein aryl is selected from phenyl, naphthyl, pyridyl, isoquinolinyl, and thienyl; R 3a and R 3b are independently selected from (1) H, (2) halogen, (3) C 1-6 alkyl, (4) hydroxy, (5) cyano, (6) nitro, (7) C 1-6 alkoxy, and (8) trifluoromethyl; R 4 is selected from (1) H, (2) C 1-4 alkyl, optionally substituted with 1-5 halogen atoms, (3) C 3-7 cycloalkyl, (4) (CH 2 ) p CO 2 R d , and (5) (CH 2 ) p CONR b R c ; R b and R c are independently selected from (1) H, and (2) C 1-6 alkyl, or R b and R c together complete a 4- to 7-membered ring optionally containing a ring O or N—R d group; R d is H or C 1-4 alkyl, m is 0,1 or 2; n is 0 to 10; and p is 1 or 2.